Stage IV HER2-Positive Breast Cancer: Anne's Patient Story
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Biomarkers
- HER2-positive
- Spread to
- bones, liver
- Treatment
- chemotherapy and targeted therapy
- Outcome
- Responding Well
Treatment course, step by step
- She responded well to her first chemotherapy regimen.
- Her first-line therapy included the HER2-targeted antibodies Herceptin and pertuzumab.
- She remained on that HER2-targeted treatment for 6 years.
What happened, in summary
Anne Keane was diagnosed in 2016 after pain in her sternum led to testing that found HER2-positive breast cancer already involving her bones and liver. She was a young mother, and learning that the disease was metastatic and incurable was devastating. At 42, she was still working full-time, raising her daughter Ruby, and trying to make room for an active life around ongoing treatment. Anne responded well to her first chemotherapy regimen. Her first-line therapy also included the HER2-targeted antibodies Herceptin and pertuzumab. The treatment worked far longer than expected, and she remained on the same HER2-targeted approach for 6 years with what her oncologist called an extraordinary response. Support from her care team and from other young people living with metastatic breast cancer helped Anne move beyond the early emotional fog of diagnosis. She returned to swimming and running and continued balancing treatment with work and parenting. In October 2021, she ran the Boston Marathon to raise money for cancer research. Her approach to metastatic breast cancer became centered on continuing to live fully while staying engaged with long-term treatment.
Where this story comes from
This is a lay summary of an account first published by Dana-Farber. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer